[Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin].
OBJECTIVE
To assess the feasibility and efficiency of the screening for hepatocarcinoma in a cohort of cirrhoseis mainly of alcoholic origin.


METHODS
293 patients with cirrhosis, among them 186 (63.5%) from alcoholic origin, were included in a surveillance programme for hepatocarcinoma by carrying out liver ultrasonography and alpha-foetoprotein dosage every 6 months. Results were analyzed with a mean follow-up of 60 months. Seventeen hepatocarcinoma discovered through the surveillance programme ("screened HCC") were compared with 40 hepatocarcinoma discovered outside the surveillance programme during the same period ("incidental HCC").


RESULTS
The alcoholic origin of the cirrhosis was a predictive factor of poor compliance to the surveillance programme. Among the 186 patients with alcoholic cirrhosis, 129 (69%) were lost during the surveillance programme due to lack of compliance (97 cases) or death (32 cases). By comparison, among the 65 patients with hepatitis C-related cirrhosis, 18 were lost by lack of compliance (11 cases) or death (7 cases) (P<0.001). Moreover, sustained or relapsing alcohol abuse after inclusion in the surveillance programme were also related to the quality of the compliance. Seventeen hepatocarcinoma were discovered through the surveillance giving an annual incidence of 2% for the emergence of hepatocarcinoma. The comparison between screened (n=17) and incidental (n=40) hepatocarcinoma showed that screened HCC were more often asymptomatic (P<0.01), were more often a solitary nodule less than 5 cms (P<0.001) and underwent more often curative treatment (P=0.02). However, the survival between screened and incidental hepatocarcinoma was not different.


CONCLUSIONS
Screening for hepatocarcinoma in patients with alcoholic cirrhosis is a difficult task due to poor compliance and early death. According to our results, a surveillance every 6 months is sufficient to detect early lesions accessible to curative treatment by surgical resection or transcutaneous ablation.
Henrion
Jean
J
Unité d'Hépato-Gastroentérologie, Centre Hospitalier de Jolimont-Lobbes, Belgique. jeanhenrion@yahoo.fr
Libon
Ernest
E
De Maeght
Stéphane
S
Deltenre
Pierre
P
Schapira
Michaël
M
Ghilain
Jean-Michel
JM
Maisin
Jean-Marc
JM
Heller
Francis R
FR
D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality; D015331:Cohort Studies; D005240:Feasibility Studies; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000175:diagnosis / Q000821:virology*; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications* / Q000175:diagnosis; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality; D008297:Male; D008403:Mass Screening / Q000379:methods* / Q000523:psychology / Q000592:standards; D008875:Middle Aged; D010349:Patient Compliance / Q000523:psychology; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D014463:Ultrasonography / Q000379:methods / Q000592:standards; D000509:alpha-Fetoproteins / Q000378:metabolism
D000509:alpha-Fetoproteins